BIAXIN 250 MG / 5 ML
CLARITHROMYCIN : 250 MG / 5 ML · DIN 02244641 · BGP PHARMA ULC
Health Canada status: MARKETED
What is BIAXIN?
BIAXIN 250 MG / 5 ML contains CLARITHROMYCIN : 250 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02244641, held by BGP PHARMA ULC, supplied as GRANULES FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 26-Apr-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BIAXIN used for?
Upper/lower respiratory tract infections, uncomplicated skin infections, mycobacterial infections (MAC), and eradication of H. pylori to reduce duodenal ulcer recurrence.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is BIAXIN called?
The same molecule, CLARITHROMYCIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Klacid | Latin | Australia, Bahrain, Czechia |
| FROMILID | Latin | Czechia |
| CLARIDAR | Latin | Bahrain, Saudi Arabia |
| CLARITHROMYCIN TEVA | Latin | Czechia |
| KLACID SR | Latin | Czechia |
| CLARITHROMYCIN OLIKLA | Latin | Czechia |
| CLARITT | Latin | Bahrain |
| CLARITT XL | Latin | Bahrain |
| Claritt® XL | Latin | United Arab Emirates |
| CLARIVA | Latin | Bahrain |
| FROMILID UNO | Latin | Czechia |
| KLACID-XL | Latin | Bahrain |
| SPECTROMAX | Latin | Bahrain |
| CLAREX | Latin | Bahrain |
| Claribax | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02244641 |
|---|---|
| Brand name | BIAXIN |
| Generic / active ingredient | CLARITHROMYCIN : 250 MG / 5 ML |
| Manufacturer | BGP PHARMA ULC |
| Strength | 250 MG / 5 ML |
| Dosage form | GRANULES FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01FA09 CLARITHROMYCIN |
| AHFS class | 08:12.12.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Apr-2016 |
| Original market date | 2002-05-28 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02244641 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2244641 |
| Brand name | BIAXIN |
| Active ingredient / INN | CLARITHROMYCIN : 250 MG / 5 ML |
| ATC code | J01FA09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.12.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BGP PHARMA ULC |
How is it administered?
Adults: 250-500 mg every 12 hours for 7-14 days. Pediatrics: 15 mg/kg/day divided every 12 hours. H. pylori: 500 mg BID with omeprazole and amoxicillin for 10 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted suspension: Store between 15-30°C and use within 14 days. Do not refrigerate. Discard unused portion after 14 days.
How is it supplied?
Tablets: HDPE bottles of 100. Suspension: 55 mL, 105 mL, and 150 mL HDPE bottles with a graduated syringe.
Which pack is which?
| Strength on the label | 250 MG / 5 ML |
|---|---|
| Dosage form | GRANULES FOR SUSPENSION |
| Route | ORAL |
| Packaging as described in the monograph | Tablets: HDPE bottles of 100. Suspension: 55 mL, 105 mL, and 150 mL HDPE bottles with a graduated syringe. |
| Storage | Reconstituted suspension: Store between 15-30°C and use within 14 days. Do not refrigerate. Discard unused portion after 14 days. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Contraindications
Hypersensitivity to macrolides; history of cholestatic jaundice; severe hepatic failure with renal impairment; QT prolongation; electrolyte disturbances; many drug interactions (see monograph).
Warnings and precautions
Serious hypersensitivity reactions; potential for poorer survival in HIV patients at high doses; exacerbation of myasthenia gravis; QT prolongation risk; hepatic and renal dysfunction.
What can be used instead?
Other Canadian products sharing ATC code J01FA09 CLARITHROMYCIN. 21 of 45 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CLARITHROMYCIN | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02274744 |
| APO-CLARITHROMYCIN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02274752 |
| APO-CLARITHROMYCIN XL | 500 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02413345 |
| BIAXIN | 125 MG / 5 ML | GRANULES FOR SUSPENSION | BGP PHARMA ULC | MARKETED | DIN 02146908 |
| BIAXIN BID | 250 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 01984853 |
| BIAXIN BID | 500 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02126710 |
| CLARITHROMYCIN | 250 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02324482 |
| CLARITHROMYCIN | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442469 |
| CLARITHROMYCIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02466120 |
| CLARITHROMYCIN | 500 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02324490 |
How much does CLARITHROMYCIN cost around the world?
CLARITHROMYCIN is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 40 | 45 | SAR███.██ |
| South Africa | single exit price | 33 | 39 | ZAR███.██ |
| Greece | producer price (ex-factory) | 30 | 30 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 8 | 29 | CZK███.██ |
| United States | acquisition | 4 | 25 | USD███.██ |
| Bahrain | retail (max) | 14 | 24 | BHD███.██ |
| Romania | max producer price | 16 | 23 | RON███.██ |
| United Arab Emirates | public | 18 | 21 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 15 | 21 | EUR███.██ |
| Luxembourg | reimbursement | 10 | 10 | EUR███.██ |
| United Kingdom | hospital | 6 | 6 | GBP███.██ |
| Australia | ex-manufacturer | 4 | 5 | AUD███.██ |
278 pack listings across 198 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every CLARITHROMYCIN pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.